7wu1wm0 发表于 2024-6-15 16:35:50

2021ESMO精彩集锦！四大癌症重磅发展一览！


    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_gif/5klfMQpnRNgUEexeKLvicP9CDJXsKrNDAvaiaWwhdYDRIibxlqmAE0IodicchNCNCAUF9GAM2Zia4JPxMicGByvFLqxQ/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">ESMO大会是欧洲最具影响力的肿瘤学平台，<span style="color: black;">亦</span>是<span style="color: black;">全世界</span>最大的肿瘤盛会之一，致力于让癌症<span style="color: black;">病人</span><span style="color: black;">得到</span>最佳结果。2021年9月16日至21日的ESMO大会受疫情影响仍然以线上形式召开。此次盛会上，除了各大癌症的前沿<span style="color: black;">药品</span>更新了临床数据，<span style="color: black;">针对</span>非小细胞肺癌，乳腺癌，胃癌，结直肠癌等这些<span style="color: black;">平常</span>肿瘤，<span style="color: black;">亦</span>涌现出了众多令人振奋的新药，璀璨夺目，给病友们带来全新的治疗<span style="color: black;">选取</span>和<span style="color: black;">期盼</span>。<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部为<span style="color: black;">大众</span>整理了四大癌种的重磅<span style="color: black;">科研</span><span style="color: black;">发展</span>，在抗癌的道路上为您点亮<span style="color: black;">期盼</span>之光！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/CwkERAMhICy3IGiaiarZDf0hLpiaftM6VjJ2KS6Q6NTahlBgaPvkjMwR4SnBtmiaOezjAslia2DtBJweClCcs44gNwA/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p><strong style="color: blue;"><span style="color: black;">肺 癌 篇</span></strong><strong style="color: blue;">0</strong><strong style="color: blue;">1</strong><strong style="color: blue;"><span style="color: black;">超过一半<span style="color: black;">病人</span>持久响应！DS-8201治疗HER+肺癌<span style="color: black;">潜能</span>巨大</span></strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在临床<span style="color: black;">实验</span>中，Trastuzumab Deruxtecan(T-DXd，DS-8201)在超过一半的 HER2 突变非小细胞肺癌<span style="color: black;">病人</span>中产生持久反应。</p>
    <span style="color: black;">大约 3% 的非鳞状非小细胞肺癌<span style="color: black;">拥有</span>HER2（<span style="color: black;">亦</span><span style="color: black;">叫作</span>为ERBB2）突变——在美国每年有近 6,000 例新病例。这些肿瘤在从不吸烟的人群中比有吸烟史的人群中更<span style="color: black;">平常</span>，<span style="color: black;">一般</span>预后较差，并且经常转移到大脑。虽然靶向 HER2 蛋白的<span style="color: black;">药品</span>已成功用于治疗该蛋白供过于求的乳腺癌和胃癌，但<span style="color: black;">日前</span><span style="color: black;">无</span>一种<span style="color: black;">药品</span>被<span style="color: black;">准许</span>用于 NSCLC <span style="color: black;">病人</span>。<span style="color: black;">因此呢</span>，这些<span style="color: black;">病人</span>只能<span style="color: black;">选取</span>化疗或免疫治疗，效果<span style="color: black;">不睬</span>想。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在今年的ESMO大会上，一项名为 DESTINY-Lung01 的 2 期临床<span style="color: black;">实验</span>数据非常振奋人心，并<span style="color: black;">发布</span>在《新英格兰医学杂志》上。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">该<span style="color: black;">实验</span>招募了 91 名<span style="color: black;">病人</span>。其中</span><span style="color: black;"><strong style="color: blue;">超过一半（54.9%）</strong></span><span style="color: black;">对DS-8201有客观反应，这<span style="color: black;">寓意</span>着<span style="color: black;">她们</span>的癌症得到<span style="color: black;">掌控</span>或缩小。对<span style="color: black;">药品</span>有反应的<span style="color: black;">病人</span>的中位<span style="color: black;">存活</span>期为 17.8 个月。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Trastuzumab Deruxtecan(T-DXd，DS-8201)是一种抗体欧联<span style="color: black;">药品</span>，由一种<span style="color: black;">叫作</span>为拓扑异构酶 I <span style="color: black;">控制</span>剂的<span style="color: black;">药品</span>结合的 HER2 靶向抗体<span style="color: black;">构成</span>，该<span style="color: black;">控制</span>剂可阻止癌细胞复制其 DNA，从而<span style="color: black;">引起</span>其死亡。这种<span style="color: black;">药品</span>已被<span style="color: black;">准许</span>用于治疗过度表达 HER2 蛋白的乳腺癌和胃癌；在非小细胞肺癌中，<span style="color: black;">日前</span>正在进行临床<span style="color: black;">实验</span>，结果<span style="color: black;">表示</span>超过一半的携带HER2基因突变的非小细胞肺癌(NSCLC)<span style="color: black;">病人</span>肿瘤停止生长或缩小了很<span style="color: black;">长期</span>，<span style="color: black;">针对</span>HER2阳性的肺癌<span style="color: black;">病人</span><span style="color: black;">来讲</span>是全新的<span style="color: black;">期盼</span>，<span style="color: black;">咱们</span>期待这一适应症能尽快上市。</span></p><strong style="color: blue;">0</strong><strong style="color: blue;">2</strong><strong style="color: blue;"><span style="color: black;">疾患</span><span style="color: black;">掌控</span>率100%！免疫“双抗”AK104效果效果<span style="color: black;">明显</span></strong>
    <h1 style="color: black; text-align: left; margin-bottom: 10px;"><span style="color: black;">免疫“双抗”<span style="color: black;">因为</span>疗效更优于免疫+化疗或“双免疫”<span style="color: black;">方法</span>，且在安全性方面<span style="color: black;">优良</span>非常<span style="color: black;">显著</span>，<span style="color: black;">病人</span>承受的严重副<span style="color: black;">功效</span>更少而<span style="color: black;">作为</span>新的<span style="color: black;">科研</span>热点。</span></h1>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">本届ESMO公开了</span><span style="color: black;"><strong style="color: blue;">国研PD-1/CTLA-4免疫“双抗”，Cadonilimab（AK104）</strong></span><span style="color: black;">的最新数据，卓越的临床数据震撼全场。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">AK104是一款免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂，能够<span style="color: black;">同期</span><span style="color: black;">控制</span>PD-1与CTLA-4这两类免疫<span style="color: black;">检测</span>点。<span style="color: black;">日前</span>，这款<span style="color: black;">药品</span><span style="color: black;">已然</span>在宫颈癌的适应症上<span style="color: black;">得到</span>了FDA授予的优先审查资格（2021年6月18日）。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">ESMO更新数据<span style="color: black;">表示</span>，在17例初治的、PD-L1表达阳性的<span style="color: black;">病人</span><span style="color: black;">其中</span>，12例<span style="color: black;">病人</span>达到了临床部分缓解，整体的缓解率高达</span><span style="color: black;"><strong style="color: blue;">70.6%</strong></span><span style="color: black;">！<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率更高，为</span><span style="color: black;"><strong style="color: blue;">94.1%</strong></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/PkPJ90j9ow3pvaQAMibTKjRPYsjuJvsRaEdle7ibGhia7jTynZl3TXogjauUdjCGicriaCECbX2sezv3kBjoTa8Eseg/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">另外</span>，还有6例曾经接受过PD-1/L1<span style="color: black;">控制</span>剂治疗的<span style="color: black;">病人</span>接受了治疗，其中1例<span style="color: black;">病人</span>达到了部分缓解，缓解率16.7%；但所有6例<span style="color: black;">病人</span>的病灶都有不同程度的缩小，<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率达到了</span><span style="color: black;"><strong style="color: blue;">100%</strong></span><span style="color: black;">！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/PkPJ90j9ow3pvaQAMibTKjRPYsjuJvsRahEiaxa2qNAY0vjyia4gfiaS19IZujmEqOamztK7Gy8f4hbELkhNy0icusQ/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">每一个数据都在为<span style="color: black;">咱们</span>带来新的惊喜。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>，<span style="color: black;">以上</span>23例患者均在继续接受治疗。其中初治<span style="color: black;">病人</span>接受治疗时间最长的，<span style="color: black;">已然</span>超过了32周，经治<span style="color: black;">病人</span>接受治疗时间最长的，<span style="color: black;">已然</span>超过了5个月。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">好<span style="color: black;">信息</span>是，这款<span style="color: black;">药品</span><span style="color: black;">日前</span>正在临床招募宫颈癌<span style="color: black;">病人</span>，想参加的<span style="color: black;">病人</span><span style="color: black;">能够</span>致电<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部进行初步<span style="color: black;">评定</span>。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/PkPJ90j9ow3pvaQAMibTKjRPYsjuJvsRaQxHoicHztBXKwKFy9bp9PicNLZPib5R2rw6E3bsu5GbRhI1kr72J46W6Q/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p><strong style="color: blue;">0</strong><strong style="color: blue;">3</strong><strong style="color: blue;"><span style="color: black;">Tedopi肺癌疫苗<span style="color: black;">面世</span>！<span style="color: black;">作为</span>晚期肺癌<span style="color: black;">病人</span>的新<span style="color: black;">期盼</span>！</span></strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在2021年9月20日的欧洲肿瘤内科学会年会（ESMO）上，OSE Immunotherapeutics<span style="color: black;">机构</span>宣布其新型抗癌疫苗Tedopi在非小细胞肺癌的Ⅲ期临床<span style="color: black;">实验</span>的<span style="color: black;">最后</span><span style="color: black;">周期</span>（代号为Atalante 1）取得了阳性结果，</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxpR2jKyWZsUGiaib3XGhqeWtGn8UsTendbkZkRfer4a5olIpkrlhj1Nx2U7n9jp6ambicEicNzDVp3PA/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在最新<span style="color: black;">颁布</span>的这项<span style="color: black;">全世界</span>多中心进行的名为Atalante 1的3期临床<span style="color: black;">实验</span>中，纳入了219名IIIB期或转移IV期的HLA-A2阳性<span style="color: black;">病人</span>，这些<span style="color: black;">病人</span><span style="color: black;">所有</span>是经过<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂失败后，<span style="color: black;">必须</span>第二或第三线治疗的<span style="color: black;">病人</span>，2:1随机分为Tedopi疫苗治疗组或化疗组（培美曲塞或多西他赛）。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">结果<span style="color: black;">表示</span>：</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在可<span style="color: black;">评定</span>的118名<span style="color: black;">病人</span>中，疫苗治疗组的1年总<span style="color: black;">存活</span>期<span style="color: black;">明显</span>改善，与化疗组相比为11.1个月VS7.5个月。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">结果<span style="color: black;">表示</span>，在晚期 HLA-A2+ NSCLC <span style="color: black;">病人</span>中，<span style="color: black;">针对</span>PD-1耐药的<span style="color: black;">病人</span>，Tedopi疫苗能够<span style="color: black;">明显</span><span style="color: black;">增多</span><span style="color: black;">病人</span>的一年总<span style="color: black;">存活</span>期。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">不得不说，Tedopi为晚期及PD-1治疗耐药后走投<span style="color: black;">没</span>路的<span style="color: black;">病人</span><span style="color: black;">供给</span>了新的<span style="color: black;">选取</span>和<span style="color: black;">期盼</span>！</span></p><strong style="color: blue;"><span style="color: black;">乳 腺 癌 篇</span></strong><strong style="color: blue;">0</strong><strong style="color: blue;">1</strong><strong style="color: blue;"><span style="color: black;">存活</span>期延长12个月以上！<span style="color: black;">Kisqali</span>最新结果<span style="color: black;">颁布</span></strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2021年9月20日，CDK4/6<span style="color: black;">控制</span>剂Kisqali（ribociclib）与来曲唑（letrozole）联用，治疗HR阳性，HER2阴性的绝经后晚期或转移性乳腺癌<span style="color: black;">病人</span>的<span style="color: black;">最后</span>结果<span style="color: black;">颁布</span>。与安慰剂和来曲唑联用相比，在中位随访时间超过6.5年时，Kisqali组合将<span style="color: black;">病人</span>的中位总<span style="color: black;">存活</span>期延长1年以上（63.9VS51.4个月）。</span></p><strong style="color: blue;">0</strong><strong style="color: blue;">2</strong>
    <h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;"><span style="color: black;">Pembrolizumab一线治疗转移性三阴乳腺癌<span style="color: black;">明显</span>改善总<span style="color: black;">存活</span>率</span></strong></h1>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2021年9月20日<span style="color: black;">颁布</span>了在 3</span><span style="color: black;"> 期 KEYNOTE-355 <span style="color: black;">实验</span>中<span style="color: black;">运用</span>一线派姆单抗联合化疗<span style="color: black;">做为</span>转移性三阴性乳腺癌<span style="color: black;">病人</span>治疗的总<span style="color: black;">存活</span>数据。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在接受 pembrolizumab 治疗的<span style="color: black;">病人</span>中，总<span style="color: black;">存活</span>期（OS）显着改善。差异近7个月，16.1vs23个月。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在 24 个月时，对照组中有 34% 的<span style="color: black;">病人</span>存活，而派姆单抗组中 CPS 为 10 或更高的<span style="color: black;">病人</span>中有 48.2% 存活。</span></p><strong style="color: blue;"><span style="color: black;">胃 癌 篇</span></strong><strong style="color: blue;">0</strong><strong style="color: blue;">1</strong><strong style="color: blue;"><span style="color: black;">一线治疗胃癌缓解率达53%！HER2单抗+PD-1疗效<span style="color: black;">明显</span></span></strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2021年9月16日，MacroGenics<span style="color: black;">机构</span><span style="color: black;">颁布</span>了其HER2单抗Margenza（margetuximab-cmkb，玛格妥昔单抗）与抗PD-1抗体联用，一线治疗HER2阳性，PD-L1阳性的胃食管腺癌（GEA）<span style="color: black;">病人</span>的临床结果。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">截止</span>2021年7月19日，在40名<span style="color: black;">能够</span><span style="color: black;">评定</span>疗效的<span style="color: black;">病人</span>中，21名<span style="color: black;">得到</span>缓解（53%，95% CI， 36%-69%）。在接受过<span style="color: black;">最少</span>一次病灶扫描的41名<span style="color: black;">病人</span>中，32名<span style="color: black;">病人</span>的肿瘤缩小（78%）。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">病人</span>的<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率为73%，中位缓解<span style="color: black;">连续</span>时间为10.3个月，中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期为6.4个月。在12和18个月时，总<span style="color: black;">存活</span>率为85%。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Margenza与曲妥珠单抗同为靶向HER2的单克隆抗体<span style="color: black;">药品</span>。单克隆抗体的结构分为抗原结合片段（Fab）和结晶片段（FC）两部分，Margenza对FC部分的结构进行了进一步的优化，<span style="color: black;">因此呢</span><span style="color: black;">能够</span>取得更好的疗效。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>，Margenza<span style="color: black;">已然</span><span style="color: black;">得到</span><span style="color: black;">准许</span>治疗HER2阳性乳腺癌<span style="color: black;">病人</span>。<span style="color: black;">开发</span><span style="color: black;">机构</span>MacroGenics正与再鼎医药合作，计划将Margenza的临床<span style="color: black;">实验</span>推广至中国及其它华人地区。<span style="color: black;">日前</span>，Margenza治疗曾经过曲妥珠单抗治疗的HER2阳性乳腺癌<span style="color: black;">病人</span>的临床<span style="color: black;">实验</span>正在进行，<span style="color: black;">能够</span>咨询全球肿瘤<span style="color: black;">大夫</span>网医学部（400-666-7998）<span style="color: black;">认识</span>详情。</span></p><strong style="color: blue;">0</strong><strong style="color: blue;">2</strong><strong style="color: blue;"><span style="color: black;">客观缓解率75%！双特异性抗体ZW25一线治疗HER2+胃癌疗效强劲！</span></strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Zanidatamab（扎尼达他单抗，代号为ZW25）是一种基于Zymeworks的Azymetric TM 平台的双特异性抗体，其<span style="color: black;">能够</span><span style="color: black;">同期</span>结合HER2的两个非重叠表位，<span style="color: black;">叫作</span>为双互补位结合，<span style="color: black;">能够</span>双重阻断HER2信号，<span style="color: black;">增多</span>HER2蛋白从细胞表面的结合和去除，<span style="color: black;">拥有</span>更强的抗HER2驱动肿瘤生长的<span style="color: black;">功效</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICzACHK1ia2JBpOq694QeFrBJxkW1cTDI8ncA45k3Hb4Ljc1kMqzckdHibw2dZpe1UqEtoRahibvXK5Ug/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">这般</span>一个新型双特异性抗体，跨癌肿有效，副<span style="color: black;">功效</span>轻微，令学术界<span style="color: black;">非常</span>激动。</span></p>
    <h1 style="color: black; text-align: left; margin-bottom: 10px;"><span style="color: black;">2021年ESMO大会上，Zanidatamab 2 期临床<span style="color: black;">实验</span><span style="color: black;">颁布</span>了一线治疗 HER2 阳性胃食管腺癌 (GEA)&nbsp;卓越数据！</span></h1>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">对 36 名表达 HER2 的 GEA <span style="color: black;">病人</span>接受了扎尼达他单抗联合 CAPOX（卡培他滨/奥沙利铂；n=14）、FP（5FU/顺铂；n=2） ，或 mFOLFOX6（5FU/亚叶酸/奥沙利铂；n=20）治疗，<span style="color: black;">无</span><span style="color: black;">病人</span>之前接受过 HER2 靶向治疗。在28名可<span style="color: black;">评定</span>的<span style="color: black;">病人</span>中：</span></p><span style="color: black;">已确认的总体客观缓解率 (cORR) 为</span><span style="color: black;"><strong style="color: blue;">75%</strong></span><span style="color: black;">&nbsp;，<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率 (DCR) 为 </span><span style="color: black;"><strong style="color: blue;">89%</strong></span><span style="color: black;">；</span><span style="color: black;"><strong style="color: blue;">扎尼达他单抗 + CAPOX/FP组的<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率高达100%</strong></span><span style="color: black;">；</span><span style="color: black;">中位缓解<span style="color: black;">连续</span>时间 (mDOR) 为 16.4 个月，中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期 (mPFS) 为 12 个月；</span><span style="color: black;">除一名<span style="color: black;">病人</span>外，所有<span style="color: black;">病人</span>的肿瘤<span style="color: black;">体积</span>均有所减少，在数据截止时，61% 的<span style="color: black;">病人</span>仍在接受治疗！</span><span style="color: black;">数据支持扎尼达他单抗 + 化疗<span style="color: black;">做为</span>一线 HER2 阳性 GEA 潜在新护理标准的<span style="color: black;">基本</span></span><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICz6xUJSEh3MKGfRm6Uu3UeXGsXvkCMmfnRUL6C2x4NqlHHnamkKiad9WMkslAYDC83Yw7qeHPAwicXg/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;"><span style="color: black;">Zanidatamab与不同化疗联用，在28名<span style="color: black;">病人</span>中<span style="color: black;">引起</span>27名<span style="color: black;">病人</span>肿瘤缩小（<span style="color: black;">照片</span><span style="color: black;">源自</span>：Zymeworks官网）</span></strong></h1><strong style="color: blue;"><span style="color: black;">结 直 肠 癌</span></strong><strong style="color: blue;">0</strong><strong style="color: blue;">1</strong><strong style="color: blue;"><span style="color: black;"><span style="color: black;">疾患</span><span style="color: black;">掌控</span>率100%！Adagrasib&nbsp;+西妥昔单抗<span style="color: black;">作为</span>KRAS+结直肠癌<span style="color: black;">病人</span>新<span style="color: black;">期盼</span></span></strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">Adagrasib（MRTX849，阿达格拉西布）</strong></span><span style="color: black;">是一款针对KRAS G12C突变体的特异性优化口服<span style="color: black;">控制</span>剂。<span style="color: black;">经过</span>在非活性状态下与KRAS G12C不可逆转地<span style="color: black;">选取</span>性结合，阻止其发送细胞生长信号并<span style="color: black;">引起</span>癌细胞死亡。MRTX849在治疗携带KRAS G12C基因突变的非小细胞肺癌（NSCLC）和结直肠癌（CRC）及其他实体肿瘤时表现出可喜的安全性和抗癌活性。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/CwkERAMhICzRiaAhPcHl0V4RZg3Wshia2uqvecGd9FqgEuucAicj6PT4xxFnRlTsliawM6gNU9M85fmIzdrl8WFNjQ/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2021年9月19日的ESMO大会上，<span style="color: black;">颁布</span> 1/2 期 代号为KRYSTAL-1 <span style="color: black;">实验</span>的最新结果<span style="color: black;">显示</span><span style="color: black;">没</span>论单独<span style="color: black;">运用</span> Adagrasib 还是与西妥昔单抗联合<span style="color: black;">运用</span>，<span style="color: black;">针对</span><span style="color: black;">已然</span>接受过<span style="color: black;">海量</span>预处理的 KRAS G12C 突变型结直肠癌<span style="color: black;">病人</span>，都看到了令人鼓舞的抗肿瘤活性和安全性。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">实验</span>结果：</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">截止</span> 2021 年 5 月 25 日，参加adagrasib单药治疗组的80% <span style="color: black;">病人</span>（n=46）接受了<span style="color: black;">最少</span>两种先前的全身抗癌治疗，中位随访时间为 8.9 个月。在可<span style="color: black;">评定</span>的<span style="color: black;">病人</span> (n=45) 中，结果<span style="color: black;">表示</span><span style="color: black;">科研</span>人员<span style="color: black;">评定</span>的缓解率 (RR) 为 </span><span style="color: black;"><strong style="color: blue;">22%</strong></span><span style="color: black;">，其中<span style="color: black;">包含</span> 1 名未经证实的部分缓解 (PR)，<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率 (DCR)</span><span style="color: black;"><strong style="color: blue;">87%</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">；中位缓解<span style="color: black;">连续</span>时间 (DOR) 为 4.2 个月。在所有入组<span style="color: black;">病人</span>中，中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期 (PFS) 为 5.6 个月。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICz6xUJSEh3MKGfRm6Uu3UeXPKIww9hdYj0hxuPC9PCjwOuqXo94esSnftFdGT7ZjB2S66XsScks0Q/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">截止</span> 2021 年 7 月 9 日，参加adagrasib 加西妥昔单抗组的90% <span style="color: black;">病人</span>（n = 32）接受了<span style="color: black;">最少</span>两种先前的全身抗癌治疗，并且中位随访时间为 7 个月。在可<span style="color: black;">评定</span>的<span style="color: black;">病人</span> (n=28) 中，结果<span style="color: black;">表示</span><span style="color: black;">科研</span>人员<span style="color: black;">评定</span>的 RR 为 43%，DCR 率为</span><strong style="color: blue;"><span style="color: black;">100%</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">。截止数据<span style="color: black;">发布</span>，63% (20/32) 的入组<span style="color: black;">病人</span>仍在接受治疗。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICz6xUJSEh3MKGfRm6Uu3UeXRB7mGtlO9yFqYonyCL5q15ibvtbMibPQ67ChucIp8sibFnpdtDW1Ytvhw/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在这项<span style="color: black;">科研</span>中，Adagrasib单药治疗和与西妥昔单抗联合治疗的耐受性良好，安全性可控。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Mirati Therapeutics<span style="color: black;">机构</span><span style="color: black;">研发</span>的</span><a style="color: black;"><span style="color: black;">adagrasib</span></a><span style="color: black;"><span style="color: black;">亦</span><span style="color: black;">已然</span>进入<span style="color: black;">重要</span>性临床<span style="color: black;">实验</span><span style="color: black;">周期</span>。<span style="color: black;">另外</span>，勃林格殷格翰（Boehringer Ingelheim），礼来（Lilly），诺华（Novartis）等多家<span style="color: black;">机构</span><span style="color: black;">亦</span>在<span style="color: black;">研发</span>直接靶向KRAS<span style="color: black;">或</span>KRAS信号通路靶点的创新疗法。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">好<span style="color: black;">信息</span>是，针对KRAS g12c突变的非小细胞肺癌和结直肠癌<span style="color: black;">病人</span>，国内多款新<span style="color: black;">药品</span><span style="color: black;">已然</span>正式<span style="color: black;">起始</span>招募<span style="color: black;">病人</span>了！</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">想申请的<span style="color: black;">病人</span><span style="color: black;">能够</span>联系<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网将医学部进行初步<span style="color: black;">评定</span>，<span style="color: black;">咱们</span><span style="color: black;">亦</span>将<span style="color: black;">即时</span>为<span style="color: black;">大众</span><span style="color: black;">供给</span>招募信息。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/CwkERAMhICyk5tnRiahnsXdoH79fwHvg0TyNcyFewiavp9vw13ZuAoCEloy2Ob6kcO0hH2vZ8E3ChpWlQB4etAMA/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></a></span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">以上是肺癌，乳腺癌，胃癌，结直肠癌<span style="color: black;">要紧</span>的新药临床数据，明天<span style="color: black;">咱们</span>将继续汇总<span style="color: black;">这次</span>盛会上其他癌症的重磅<span style="color: black;">发展</span>，敬请期待。<span style="color: black;">更加多</span>癌症的新药<span style="color: black;">新闻</span>和免费入组信息可致电<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部4006667998或添加文末二维码。</span></p>
    <h1 style="color: black; text-align: left; margin-bottom: 10px;"><span style="color: black;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">参考资料：</p>
      </span></h1>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">https://www.onclive.com/view/real-world-pfs-benefit-reported-with-pacific-regimen-in-unresectable-stage-iii-nsclc</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">本文为<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网原创，未经授权禁止转载</span></strong></p><span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网提醒<span style="color: black;">任何一款<span style="color: black;">药品</span>仅对一部分<span style="color: black;">病人</span>有效，肿瘤<span style="color: black;">必须</span>多学科综合治疗。<span style="color: black;">大众</span><span style="color: black;">能够</span><span style="color: black;">经过</span>权威专家会诊<span style="color: black;">得到</span>质子，靶向，免疫等前瞻疗法诊疗意见。<a style="color: black;">在线咨询</a></span><span style="color: black;">本文<span style="color: black;">触及</span>的新药和技术在国内<span style="color: black;">处在</span>临床<span style="color: black;">科研</span><span style="color: black;">周期</span>，细胞治疗技术<span style="color: black;">仅有</span>CAR-T疗法正式<span style="color: black;">得到</span>FDA<span style="color: black;">准许</span>，其他技术均在积极开展临床<span style="color: black;">实验</span><span style="color: black;">周期</span>。本文数据<span style="color: black;">源自</span>于<span style="color: black;">发布</span>的论文，真实<span style="color: black;">靠谱</span>。<span style="color: black;">病人</span>参加临床<span style="color: black;">实验</span>应在<span style="color: black;">大夫</span>的监管下，在医院正规<span style="color: black;">运用</span>。<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网不<span style="color: black;">意见</span><span style="color: black;">病人</span><span style="color: black;">自动</span><span style="color: black;">运用</span>本文<span style="color: black;">触及</span>的新药新技术。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">扫描添加病友群</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">最新<span style="color: black;">新闻</span>｜新技术｜新药<span style="color: black;">开发</span>｜权威专家</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">入群免费领取抗癌资料</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></p><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></p>




欢喜楊陽 发表于 2024-8-31 04:03:06

外贸B2B平台有哪些？

b1gc8v 发表于 2024-10-2 23:25:21

软文发布论坛开幕式圆满成功。 http://www.fok120.com

wrjc1hod 发表于 2024-10-13 08:36:07

谷歌网站排名优化 http://www.fok120.com/

nqkk58 发表于 2024-11-1 20:17:04

感谢你的精彩评论，为我的思绪打开了新的窗口。

b1gc8v 发表于 2024-11-9 01:05:40

楼主节操掉了，还不快捡起来！
页: [1]
查看完整版本: 2021ESMO精彩集锦！四大癌症重磅发展一览！